Dr. Jaime R. Merchan, MD

Dr. Merchan practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Merchan's NPI, 1609853464, was assigned on December 22, 2005. Dr. Merchan graduated from Universidad Catolica de Santiago de Guayaquil in 1992. Dr. Merchan holds Florida license ME74584.

Dr. Merchan's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Merchan's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Merchan practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Merchan's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Merchan is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Merchan's licenses on file in 3 states: Florida, Minnesota and Massachusetts.

Dmand AI lists colorectal cancer, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Merchan treats.

CMS data shows 481 Medicare services from Dr. Merchan across 5 procedure codes in 2024, for 110 Medicare patients. Medicare paid $28,957 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 110 Medicare patients who saw Dr. Merchan in 2024. The largest group is 65 to 74, with 47 patients. 75% of them have cancer, and 75% have high blood pressure. 25% are also on Medicaid. Their average risk score is 2.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Merchan's median patient age at 70, with 21% women.

In 2024, Dr. Merchan wrote 223 Medicare Part D claims for 47 patients. 85% of them were for generic drugs. CMS names the drug for 107 of them, across 3 drugs with 11 or more claims each, at $60,059 in total drug cost. In 2023, CMS named 143 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Merchan for performance year 2024, reported as part of a group. Dr. Merchan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Merchan as offering telehealth.

Dmand AI links 51 papers to Dr. Merchan, published from 2009 to 2024. 2023 was the busiest year, with 4. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell and Antibodies, Monoclonal, Humanized. Dr. Merchan has published most often in Lancet Oncol. Dr. Merchan's most frequent co-authors are Toni K. Choueiri, MD, Peter Joel Hosein, MBBS and Joe U. Levi, MD.

Dmand AI links Dr. Merchan to 6 clinical trials, 2 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Cholangiocarcinoma, Neoplasm Metastasis and Ureteral Neoplasms. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Merchan that name 3 trials.

CMS Open Payments shows 17 general payments to Dr. Merchan from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 49% of the total. Exelixis Inc. paid the most, $7,701. It also lists 10 research payments totaling $47,362 from 2017 to 2025, naming 3 clinical trials.

Dmand AI lists 1 award for Dr. Merchan, most recently CMS Stage 1 EHR in 2013.

Dr. Merchan graduated from Universidad Catolica de Santiago de Guayaquil in 1992. Dr. Merchan is a member of AACR and ASCO.

Dr. Merchan is in network with 10 carriers, including Elevance, Aetna and United Healthcare. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.